Get the Stockscreener App
6.66
0.45%
-0.03
Pre-market:
6.90
0.24
+3.60%
4 D Molecular Therapeutics Inc stock is traded at $6.66, with a volume of 420.23K.
It is down -0.45% in the last 24 hours and down -8.26% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$6.69
Open:
$6.72
24h Volume:
420.23K
Relative Volume:
0.40
Market Cap:
$311.04M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-2.5038
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-4.03%
1M Performance:
-8.26%
6M Performance:
+59.33%
1Y Performance:
-58.79%
1-Day Range:
$6.64
$7.05
1-Week Range:
$6.60
$7.2099
52-Week Range:
$2.235
$17.41
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
6.66 | 312.44M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Will 4D Molecular Therapeutics Inc. continue its uptrendJuly 2025 Market Mood & High Yield Stock Recommendations - newser.com
Rate Hike: What hedge funds are buying 4D Molecular Therapeutics Inc2025 Technical Patterns & Accurate Buy Signal Alerts - خودرو بانک
Pullback Watch: How sensitive is 4D Molecular Therapeutics Inc. to inflation2025 Buyback Activity & Free Real-Time Market Sentiment Alerts - خودرو بانک
4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Trend analysis for 4D Molecular Therapeutics Inc. this weekTrade Ideas & AI Powered Market Entry Ideas - newser.com
New Highs: Will 4D Molecular Therapeutics Inc outperform its industry peersJuly 2025 Price Swings & Fast Momentum Stock Entry Tips - خودرو بانک
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
Levels Update: What is the Moat Score of 4D Molecular Therapeutics IncQuarterly Trade Report & Free Technical Pattern Based Buy Signals - خودرو بانک
Sentiment Recap: Will 4D Molecular Therapeutics Inc benefit from geopolitical trendsJuly 2025 Pullbacks & Smart Allocation Stock Reports - خودرو بانک
Risk Check: Can 4D Molecular Therapeutics Inc sustain its profitabilityWeekly Investment Recap & Accurate Entry/Exit Alerts - خودرو بانک
Cubist Systematic Strategies LLC Sells 364,659 Shares of 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
What drives Millicom International Cellular SAs stock priceEarnings Recap Report & Fast Exit and Entry Strategy Plans - خودرو بانک
What MACD and RSI say about 4D Molecular Therapeutics Inc.2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Applying Wyckoff theory to 4D Molecular Therapeutics Inc. stock2025 Risk Factors & AI Based Buy and Sell Signals - newser.com
How to forecast 4D Molecular Therapeutics Inc. trends using time seriesShort Setup & Real-Time Volume Triggers - newser.com
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Biotech Leader 4DMT Issues 40,900 Restricted Stock Units to Attract Key Non-Executive Talent - Stock Titan
Building trade automation scripts for 4D Molecular Therapeutics Inc.2025 Risk Factors & AI Powered Market Entry Strategies - Newser
How moving averages guide 4D Molecular Therapeutics Inc. tradingWeekly Trade Recap & Free High Return Stock Watch Alerts - Newser
4D Molecular Therapeutics Inc. stock trendline breakdownQuarterly Earnings Report & Fast Exit/Entry Strategy Plans - Newser
Should you wait for a breakout in 4D Molecular Therapeutics Inc.Market Weekly Review & Safe Capital Growth Tips - Newser
Visual analytics tools that track 4D Molecular Therapeutics Inc. performancePortfolio Value Report & Risk Adjusted Swing Trade Ideas - Newser
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.40 Average Target Price from Analysts - MarketBeat
Ranking 4D Molecular Therapeutics Inc. among high performing stocks via toolsJuly 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - Newser
Chart based exit strategy for 4D Molecular Therapeutics Inc.Weekly Trend Summary & Risk Managed Investment Strategies - Newser
What indicators show strength in 4D Molecular Therapeutics Inc.Global Markets & Risk Controlled Daily Plans - Newser
Volume spikes in 4D Molecular Therapeutics Inc. stock – what they mean2025 Market Trends & Verified Entry Point Signals - Newser
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer - GlobeNewswire Inc.
Regression analysis insights on 4D Molecular Therapeutics Inc. performanceAnalyst Upgrade & Verified Swing Trading Watchlists - Newser
What candlestick patterns are forming on 4D Molecular Therapeutics Inc.Weekly Profit Report & Growth Focused Entry Reports - Newser
4D Molecular Therapeutics, Inc. $FDMT Shares Bought by Invesco Ltd. - MarketBeat
How to track smart money flows in 4D Molecular Therapeutics Inc.Quarterly Profit Report & Reliable Trade Execution Plans - Newser
Is 4D Molecular Therapeutics Inc. a candidate for recovery playPortfolio Return Report & Step-by-Step Trade Execution Guides - Newser
Is 4D Molecular Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 EndofMonth & Reliable Trade Execution Plans - Newser
Can 4D Molecular Therapeutics Inc. hit a new high this monthJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - Newser
Nuveen LLC Acquires Shares of 150,314 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
Detecting support and resistance levels for 4D Molecular Therapeutics Inc.Weekly Trend Recap & High Conviction Buy Zone Picks - Newser
How to escape a deep drawdown in 4D Molecular Therapeutics Inc.Weekly Profit Summary & Verified Entry Point Detection - Newser
Pattern recognition hints at 4D Molecular Therapeutics Inc. upsideDollar Strength & High Return Stock Watch Alerts - Newser
Reversal indicators forming on 4D Molecular Therapeutics Inc. stockWeekly Stock Summary & Consistent Profit Trade Alerts - Newser
Transcript : 4D Molecular Therapeutics, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 01 - MarketScreener
Real time social sentiment graph for 4D Molecular Therapeutics Inc.2025 Trading Volume Trends & High Accuracy Swing Trade Signals - Newser
Is 4D Molecular Therapeutics Inc. forming a bottoming baseWeekly Loss Report & Reliable Trade Execution Plans - Newser
Jim Cramer on 4D Molecular Therapeutics: “This is a Pure Spec” - MSN
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):